GAITHERSBURG, Md., June 28 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced the closing of its sale of $575 million
principal amount of 1.375% Convertible Senior Notes due 2011 and $575 million
principal amount of 1.625% Convertible Senior Notes due 2013 to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of 1933,
as amended (the "Securities Act"). The aggregate principal amount of
Convertible Senior Notes sold reflects the full exercise by the initial
purchasers of their option to purchase additional Convertible Senior Notes to
This notice does not constitute an offer to sell or a solicitation of an
offer to buy securities. Any offers of the securities will be made only by
means of a private offering memorandum. The securities offered have not been
registered under the Securities Act or the securities laws of any other
jurisdiction and may not be offered or sold in the United States absent
registration or an applicable exemption from registration requirements.
SOURCE MedImmune, Inc.
CONTACT: Investors: Peter Vozzo, +1-301-398-4358, or Media: Jamie Lacey,
+1-301-398-4035, both of MedImmune, Inc.